- Home
- PEPG vs HOWL Comparison
PEPG vs HOWL Comparison
Compare PEPG & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- HOWL
- Stock Information
- Founded
- PEPG 2018
- HOWL 2017
- Country
- PEPG United States
- HOWL United States
- Employees
- PEPG N/A
- HOWL N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- HOWL Health Care
- Exchange
- PEPG Nasdaq
- HOWL Nasdaq
- Market Cap
- PEPG 43.2M
- HOWL 47.1M
- IPO Year
- PEPG 2022
- HOWL 2021
- Fundamental
- Price
- PEPG $1.29
- HOWL $1.33
- Analyst Decision
- PEPG Buy
- HOWL Strong Buy
- Analyst Count
- PEPG 3
- HOWL 3
- Target Price
- PEPG $7.67
- HOWL $8.33
- AVG Volume (30 Days)
- PEPG 311.5K
- HOWL 199.3K
- Earning Date
- PEPG 08-07-2025
- HOWL 08-14-2025
- Dividend Yield
- PEPG N/A
- HOWL N/A
- EPS Growth
- PEPG N/A
- HOWL N/A
- EPS
- PEPG N/A
- HOWL N/A
- Revenue
- PEPG N/A
- HOWL N/A
- Revenue This Year
- PEPG N/A
- HOWL N/A
- Revenue Next Year
- PEPG N/A
- HOWL N/A
- P/E Ratio
- PEPG N/A
- HOWL N/A
- Revenue Growth
- PEPG N/A
- HOWL N/A
- 52 Week Low
- PEPG $0.88
- HOWL $0.60
- 52 Week High
- PEPG $10.15
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- PEPG 50.90
- HOWL 58.20
- Support Level
- PEPG $1.37
- HOWL $1.12
- Resistance Level
- PEPG $1.38
- HOWL $1.29
- Average True Range (ATR)
- PEPG 0.13
- HOWL 0.08
- MACD
- PEPG -0.01
- HOWL 0.01
- Stochastic Oscillator
- PEPG 63.64
- HOWL 75.00
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.